Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:EPRX NASDAQ:PVLA NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$84.63+2.8%$76.50$56.71▼$99.50$1.85B0.46319,454 shs340,720 shsEPRXEupraxia Pharmaceuticals$7.27-2.0%$7.41$3.67▼$9.32$448.42M1.19175,908 shs193,073 shsPVLAPalvella Therapeutics$129.47+1.5%$125.56$20.20▼$151.18$1.83B-0.13200,671 shs212,304 shsRXRXRecursion Pharmaceuticals$3.37-4.3%$3.40$2.80▼$7.18$1.86B1.0511.28 million shs13.40 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+0.99%+8.33%+0.64%+10.20%EPRXEupraxia Pharmaceuticals0.00%+9.43%+10.04%-13.01%+97.00%PVLAPalvella Therapeutics0.00%-1.40%+2.74%+58.73%+418.56%RXRXRecursion Pharmaceuticals0.00%-2.59%+9.00%-17.32%-40.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$84.63+2.8%$76.50$56.71▼$99.50$1.85B0.46319,454 shs340,720 shsEPRXEupraxia Pharmaceuticals$7.27-2.0%$7.41$3.67▼$9.32$448.42M1.19175,908 shs193,073 shsPVLAPalvella Therapeutics$129.47+1.5%$125.56$20.20▼$151.18$1.83B-0.13200,671 shs212,304 shsRXRXRecursion Pharmaceuticals$3.37-4.3%$3.40$2.80▼$7.18$1.86B1.0511.28 million shs13.40 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+0.99%+8.33%+0.64%+10.20%EPRXEupraxia Pharmaceuticals0.00%+9.43%+10.04%-13.01%+97.00%PVLAPalvella Therapeutics0.00%-1.40%+2.74%+58.73%+418.56%RXRXRecursion Pharmaceuticals0.00%-2.59%+9.00%-17.32%-40.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.88Moderate Buy$107.3326.83% UpsideEPRXEupraxia Pharmaceuticals 2.75Moderate Buy$15.00106.33% UpsidePVLAPalvella Therapeutics 2.93Moderate Buy$198.0752.99% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$9.20173.00% UpsideCurrent Analyst Ratings BreakdownLatest EPRX, PVLA, ANIP, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/31/2026PVLAPalvella Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$210.00 ➝ $240.003/24/2026PVLAPalvella Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$255.00 ➝ $270.003/23/2026EPRXEupraxia Pharmaceuticals William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform3/17/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/17/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$883.37M2.15$10.21 per share8.29$24.03 per share3.52EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/APVLAPalvella Therapeutics$42.81M43.31N/AN/A$2.36 per share54.86RXRXRecursion Pharmaceuticals$74.26M23.94N/AN/A$2.14 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$78.34M$3.3625.199.54N/A8.87%27.97%9.70%5/8/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.03N/AN/AN/AN/A-167.68%-66.72%5/6/2026 (Estimated)PVLAPalvella Therapeutics-$41.72M-$3.71N/AN/AN/AN/A-98.14%-59.66%5/7/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.48N/AN/AN/A-863.37%-63.98%-47.05%5/6/2026 (Estimated)Latest EPRX, PVLA, ANIP, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28N/AN/AN/A$207.63 millionN/A5/7/2026Q1 2026PVLAPalvella Therapeutics-$0.90N/AN/AN/AN/AN/A5/6/2026N/AEPRXEupraxia Pharmaceuticals-$0.22N/AN/AN/AN/AN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.27N/AN/AN/A$15.79 millionN/A3/31/2026Q4 2025PVLAPalvella Therapeutics-$0.95-$1.08-$0.13-$1.08N/AN/A3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/A2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.112.712.19EPRXEupraxia PharmaceuticalsN/A15.1215.12PVLAPalvella TherapeuticsN/A5.205.20RXRXRecursion Pharmaceuticals0.015.505.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%EPRXEupraxia PharmaceuticalsN/APVLAPalvella Therapeutics40.11%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals8.10%EPRXEupraxia PharmaceuticalsN/APVLAPalvella Therapeutics20.50%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60022.41 million20.60 millionOptionableEPRXEupraxia Pharmaceuticals2960.43 millionN/AN/APVLAPalvella TherapeuticsN/A14.32 million11.38 millionN/ARXRXRecursion Pharmaceuticals400527.40 million482.94 millionOptionableEPRX, PVLA, ANIP, and RXRX HeadlinesRecent News About These CompaniesIs It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?May 3 at 12:08 AM | finance.yahoo.comWhat Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny StockMay 3 at 9:06 AM | finance.yahoo.comWhat Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny StockMay 3 at 6:31 AM | insidermonkey.comRecursion Pharmaceuticals: Recursion Announces Board TransitionMay 1, 2026 | finanznachrichten.deRecursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key FactsMay 1, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key FactsMay 1, 2026 | zacks.comRecursion Announces Board TransitionApril 30, 2026 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co.April 30, 2026 | marketbeat.comRecursion Announces Board TransitionApril 30, 2026 | globenewswire.comRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowApril 29, 2026 | finance.yahoo.comRecursion to Report First Quarter 2026 Business Updates and Financial Results on May 6April 29, 2026 | finance.yahoo.comRecursion to Report First Quarter 2026 Business Updates and Financial Results on May 6April 29, 2026 | globenewswire.com[Latest] Global Generative AI in Chemical Market Size/Share Worth USD 12.84 Billion by 2035 at a 24.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)April 28, 2026 | finance.yahoo.comRecursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell'April 28, 2026 | seekingalpha.comRecursion Pharmaceuticals May Be Losing Ground To Its PeersApril 27, 2026 | seekingalpha.comRecursion Pharmaceuticals (RXRX) Projected to Post Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comRecursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 PrioritiesApril 26, 2026 | finance.yahoo.comWhy Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss ForecastApril 25, 2026 | finance.yahoo.comA Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain AttentionApril 24, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketApril 23, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketApril 23, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPRX, PVLA, ANIP, and RXRX Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$84.63 +2.31 (+2.81%) Closing price 04:00 PM EasternExtended Trading$86.08 +1.46 (+1.72%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Eupraxia Pharmaceuticals NASDAQ:EPRX$7.27 -0.15 (-2.02%) Closing price 04:00 PM EasternExtended Trading$7.91 +0.64 (+8.80%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Palvella Therapeutics NASDAQ:PVLA$129.47 +1.86 (+1.46%) Closing price 04:00 PM EasternExtended Trading$129.50 +0.03 (+0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Recursion Pharmaceuticals NASDAQ:RXRX$3.37 -0.15 (-4.26%) Closing price 04:00 PM EasternExtended Trading$3.38 +0.01 (+0.45%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
